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A B S T R A C T
Background
Several interventions have been developed to promote informed consent for participants in clinical trials. However, many of these
interventions focus on the content and structure of information (e.g. enhanced information or changes to the presentation format)
rather than the process of decision making. Patient decision aids support a decision making process about medical options. Decision aids
support the decision process by providing information about available options and their associated outcomes, alongside information
that enables patients to consider what value they place on particular outcomes, and provide structured guidance on steps of decision
making. They have been shown to be effective for treatment and screening decisions but evidence on their effectiveness in the context
of informed consent for clinical trials has not been synthesised.
Objectives
To assess the effectiveness of decision aids for clinical trial informed consent compared to no intervention, standard information (i.e.
usual practice) or an alternative intervention on the decision making process.
Search methods
We searched the following databases and to March 2015: Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane
Library; MEDLINE (OvidSP) (from 1950); EMBASE (OvidSP) (from 1980); PsycINFO (OvidSP) (from 1806); ASSIA (ProQuest)
(from 1987); WHO International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/); ClinicalTrials.gov;
ISRCTN Register (http://www.controlled-trials.com/isrctn/). We also searched reference lists of included studies and relevant reviews.
We contacted study authors and other experts. There were no language restrictions.
Selection criteria
We included randomised and quasi-randomised controlled trials comparing decision aids in the informed consent process for clinical
trials alone, or in conjunction with standard information (such as written or verbal) or alongside alternative interventions (e.g. paper-
based versus web-based decision aids). Included trials involved potential trial participants, or their guardians, being asked to consider
participating in a real or hypothetical clinical trial.
1Decision aids for people considering taking part in clinical trials (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
At least two authors independently assessed studies for inclusion, extracted reported data and assessed risk of bias. Findings were pooled
where appropriate. We used GRADE to assess the quality of the evidence for each outcome.
Main results
We identified one study (290 randomised participants) that investigated the effectiveness of decision aids compared to standard
information in the informed consent process for clinical trials. This study reported two separate decision aid randomised controlled
trials (RCTs). The decision aid trials were nested within two different parent trials focusing on breast cancer in postmenopausal women.
One trial focused on informed consent for treatment in women who had previously had surgery for ductal carcinoma in situ (DCIS),
the other on informed consent for prevention in women at high risk for breast cancer. Two different decision aids were used in these
RCTs, and were compared with standard information.
The pooled findings highlight the uncertainty surrounding most reported outcomes, including knowledge, decisional conflict, anxiety,
trial participation and attrition. There was very low quality evidence that decision aids lower levels of decisional regret to a small
degree (MD -5.53, 95% CI -10.29 to -0.76). No data were identified on several prespecified primary outcomes, including accurate risk
perception, values-based decision, or whether potential participants recognised that a decision needed to be made, were able to identify
features of options that matter most to individuals, or were involved in the decision.
Authors’ conclusions
There was insufficient evidence to determine whether decision aids to support the informed consent process for clinical trials are more
effective than standard information. Additional well designed, adequately powered clinical trials in more diverse clinical and social
populations are needed to strengthen the results of this review. More generally, future research on which outcomes are most relevant
for assessment in this context would be helpful.
P L A I N L A N G U A G E S U M M A R Y
Decision aids for people deciding about taking part in clinical trials
We reviewed the evidence about the effect of specific tools, called decision aids, which aim to improve decision making in the informed
consent process for people who are considering participating in a clinical trial. These tools were compared to the standard process used
for informed consent in clinical trials. There is currently not enough evidence to draw conclusions about the effectiveness of decision
aids in the informed consent process for clinical trials.
In clinical trials, one healthcare treatment is compared to another treatment or to no treatment. Before potential participants sign a
consent form where they agree to take part in a clinical trial they must be given information about what will be expected of them
and what they can expect. Research has shown that this information is often not as good as it could be. For example, people often
misunderstand the information they have been given. Decision aids, which are tools that assist people to think about what matters most
to them, support decision making for treatment and screening. Presenting information about trial participation through decision aids
might improve the informed consent process by improving participants’ knowledge, certainty with the decision and enabling them to
consider what matters most to them personally.
We searched the literature for studies where potential trial participants were randomly allocated to receive decision aids, compared to
no decision aids or to other types of information for informed consent. We found one study, which reported data from two separate
decision aid trials, where people who were given a decision aid alongside standard information were compared to people who were
given standard information alone. When data from these two trials were combined, the results were inconclusive and not able to show
whether people given the decision aid had any more or less knowledge or uncertainty about their decision, or were more or less likely
to participate in a trial, than the people who were only given standard information. However, people who used the decision aid may
have felt less regret about their decision. Overall there was very low quality evidence to support these findings, which means that there
may be uncertainty around the results, and therefore, further research is required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Comparison 1: Decision aids for informed consent versus standard informed consent
Patient or population: people considering taking part in clinical trials
Intervention: decision aid for informed consent
Comparison: standard informed consent
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Comparison 1: Deci-
sion aid for informed
consent versus stan-
dard informed consent
Knowledge
Quality of Informed
Consent (QuIC)
Follow-up: post deci-
sion
The mean knowledge in
the control group was
87.6¹
The mean knowledge in
the intervent ion groups
was
1.68 higher
(1.91 lower to 5.26
higher)
146
(2 studies)
⊕©©©
very low²,³ ,
Accurate risk percep-
tion
See comment See comment Not est imable - See comment No study reported this
outcome
Values based decision See comment See comment Not est imable - See comment No study reported this
outcome
Recognition that a de-
cision needs to be
made
See comment See comment Not est imable - See comment No study reported this
outcome
Involvement in deci-
sion
See comment See comment Not est imable - See comment No study reported this
outcome
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Decisional conflict
Decision Conf lict Scale
Follow-up: post deci-
sion
The mean decisional
conf lict score in the
control group was 12.
55¹
The mean decisional
conf lict in the interven-
t ion groups was
3.47 higher
(1.51 lower to 8.45
higher)
146
(2 studies)
⊕©©©
very low²,³ ,
Decisional regret
Decision Regret Scale
Follow-up: 3 months
The mean decisional re-
gret score in the control
group was 18.25¹
The mean decisional re-
gret in the intervent ion
groups was
5.53 lower
(10.29 to 0.76 lower)
119
(2 studies)
⊕©©©
very low²,³ ,
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
¹ Control group scores were used to calculate the mean score across studies.
² Studies were considered at risk of bias due to a lack of blinding (part icipants, personnel and outcome assessors) and
incomplete outcome data (30% of randomised sample were excluded f rom the analysis post-randomisat ion)
³ Included trials were conducted in one populat ion only (i.e. selected groups of postmenopausal women)
The mean ef fect est imate crosses the line of no ef fect and the CI is very wide. That is, at least 25% favoured either the
intervent ion or the control.
The mean ef fect est imate does not cross the line of no ef fect but the CI is very wide.
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B A C K G R O U N D
Description of the condition
A clinical trial is an experiment in which two or more interven-
tions, possibly including a control intervention or no interven-
tion, are compared by being (often randomly) allocated to partic-
ipants. Clinical trials, and RCTs in particular, are considered the
gold standard research methodology for rigorously evaluating the
effectiveness of healthcare interventions (Pocock 1983). Increas-
ingly, clinical trials are used to inform and direct clinical practice,
and they constitute a significant component of publicly-funded re-
search. However, evidence from publicly-funded trials has shown
that approximately 70% of clinical trials fail to recruit their desired
number of participants (Campbell 2007). Failure to recruit the
required sample size can lead to trials being underpowered which
may not allow the effects of different interventions to be detected
or accurately determined. Various studies have developed different
strategies that aim to improve participant recruitment to clinical
trials (Treweek 2010).
There are several reasons for poor recruitment to clinical trials
at the patient, clinician, and organisational level (Prescott 1999;
Campbell 2007). Often, through good trial design and trial man-
agement processes, barriers with clinicians and organisational fac-
tors may be overcome (Campbell 2007). However, other patient
factors can play a role in a patient’s decision to participate in a
clinical trial, or not, and many of these directly influence the in-
dividual’s decision about participation (Prescott 1999; McCann
2013).
Patients cite many reasons for not participating in clinical trials,
including: lack of knowledge about the trial’s rationale; lack of
understanding of the methodological processes of clinical trials,
such as randomisation of treatment allocation; fears about treat-
ment efficacy; misunderstanding the concept of equipoise; and a
dislike of discussions with clinicians about treatment uncertainty
(Prescott 1999; Jenkins 2000; Featherstone 2002; Abraham 2006;
Fayter 2007; Mangset 2008). Such misunderstandings may result
in poor quality decisions about both participation and non-par-
ticipation. There may be other influences on a person’s decision
to participate in a clinical trial, such as whether the treatment op-
tions are consistent with their personal values, whether the clini-
cal trial includes outcomes that a participant considers important,
and whether participation is convenient for other reasons such as
cost, transportation, or the additional demands of trial participa-
tion. Many of the influences on people’s decisions to participate
in clinical trials may also be related to the phase of the trial. For
example, in early phase trials, people may have misconceptions
about potential benefits and risks, while in later phase trials issues
such as randomisation and equipoisemay bemore important (Cox
2003; Jenkins 2010). Furthermore, participating in a clinical trial
removes the decision about treatment from participants’ control,
which can affect their feelings of autonomy (Madsen 2002).
In response to many of the concerns about participants’ lack of
understanding of clinical trials, investigators have sought to im-
prove the informed consent process. Patients and clinicians have
identified concerns about the consent procedure and information
provided during the consent process as a barrier to participation in
clinical trials (Prescott 1999). Informed consent is a cornerstone
of ethical healthcare research and is a requirement for most clinical
research studies and clinical trials in particular. Ethical guidelines
suggest that prospective clinical trial participants should under-
stand a minimum amount of information about the trial in which
they are invited to participate to be able to provide valid informed
consent. However, poor participant understanding of the research
processes, a lack of knowledge about the expectations and demands
of trials, and insufficient support when faced with the decision,
have been demonstrated across a range of clinical areas (Prescott
1999; Jenkins 2000; Flory 2004; Nishimura 2013). Existing ap-
proaches to obtaining informed consent for research purposes are
therefore not optimal and could be improved.
Several strategies have been adopted in an attempt to improve in-
formed consent for clinical trials. These include: written informa-
tion (e.g. enhanced consent documents, simplifying language, us-
ing illustrations and altering layout); detailed verbal information;
test-feedback interventions; telephone-based interventions; com-
puter-assisted programs; audio-visual interventions; and physi-
cian-based communication training (Ellis 2002; Coyne 2003;
Angiolillo 2004; Flory 2004; Hietanen 2007; Synnot 2014; Sand
2008; Yap 2009). However, much of this empirical work has fo-
cused on the structural documents or components by aiming to
improve presentation of information, or mode of delivery, rather
than the process of decision making itself. This focus on improv-
ing information provision is further reflected in the results of these
studies, which show few significant improvements in knowledge
and understanding among trial participants when analysed to-
gether (Flory 2004; Nishimura 2013; Synnot 2014). Interestingly,
a review of these studies concluded that increasing discussion dur-
ing the informed consent process is one of the most successful
types of intervention to improve knowledge and understanding
(Flory 2004; Nishimura 2013). However, whilst knowledge and
understanding are important for decision making, they are not
the only important factors. Therefore, interventions which aim
to support the process of decision making, as well as improving
knowledge, may hold additional benefit for participants consider-
ing clinical trial participation.
It is important to reiterate that there are a range of reasons for poor
recruitment to RCTs and this review does not aim to address all
of these. This review focuses on interventions that aim to improve
the decision making process for potential trial participants.
Description of the intervention
This review considered the effectiveness of decision aids (also
called decision support tools/systems/technologies/interventions,
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interactive health communication applications, interactive health
communication systems, shared decision making programs or risk
communication tools). These decision aids are complex interven-
tions designed to help people make specific, deliberative choices
among healthcare options, by providing information about the
options and outcomes that are relevant to the decision (Stacey
2014). They provide detailed information on all aspects of the
decision and include exercises to help patients clarify what values
are important to them, and being supported to be involved (or
participate) in the decision (Stacey 2014). Specifically, decision
aids have been shown to improve knowledge of key aspects of the
decision when faced with options where there is no objectively
correct answer (clinical equipoise), promote accurate perceptions
of probabilities of outcomes, and align preferred outcomes with
the choice made (Stacey 2014).
The mode of delivery for these interventions varies, and includes:
pamphlets and booklets; audiotapes; audio-guided workbooks;
computer or web-based formats; interactive videodiscs; decision
boards and group presentations (Stacey 2014). The mode used to
deliver the decision support is often determined during the inter-
vention development stage by piloting with patients. Moreover,
these interventions are also used in varying contexts, which can
be categorised as those that are used by clinicians in face-to-face
consultations; those that can be used independently of the clinical
consultation; and those that are delivered using more interactive
technologies to supplement information given during consulta-
tions (Elwyn 2010a). The target population for these interven-
tions can be virtually any clinical population that needs patient
involvement in decision making. Within a clinical area, different
decision aids have been developed to target specific groups, such
as adults with low literacy (Clement 2009; Smith 2010). Similarly,
the decision maker in some treatment or screening decisions may
be a proxy decision maker, such as the guardian for a child or de-
pendent adult (Wallace 2006).
To determine whether an intervention meetsminimum criteria for
classification as a decision aid, we assessed all interventions from
potentially eligible studies using the International Patient Deci-
sion Aid Standards instrument (IPDASi) (Elwyn 2009b). This en-
abled us to determine whether the identified interventions could
be considered decision aids (by containing all of the qualifying
content items) rather than other educational interventions (which
do not meet the minimum content requirements).The IPDASi
instrument was developed to assess the quality of decision aids and
contains a checklist of key qualifying items, under broad domains,
to be included in such an intervention, that is, assesses key quality
requirements and creates aminimum criteria threshold. For exam-
ple, some of these domains cover provision of information about
options in sufficient detail for making a specific decision; presen-
tation of outcome probabilities; ways to clarify and express values;
and structured guidance in deliberation and communication. The
original application of this tool was to assess the quality of decision
aids (through generation of a scoring system). However, in this
instance we used the IPDASi tool to evaluate the qualifying items
of interventions. The IPDASi tool has been updated recently, and
now contains a cut-off score for determining whether or not an
intervention is a decision support intervention that assesses key
qualifying requirements and creates a minimum criteria threshold
(Joseph-Williams 2013).
Evaluations of different methods of trial recruitment almost in-
variably occur as subsidiary studies to larger clinical trials. For ex-
ample, investigators conducting a trial of two different surgical
procedures for a given condition may be interested in understand-
ing whether a decision aid helps to inform participation in said
surgical trial. For clarity, throughout this review we used the term
decision aid trial to refer to these subsidiary nested studies that
were the focus of this review, and used the term parent trial to refer
to the (often clinically focused, such as the comparison of surgical
techniques in the above example) clinical trial in which they are
set.
How the intervention might work
Preference sensitive decisions require the patient to make a best
choice when there is uncertain or no clear evidence to support one
option over another, the options have different inherent benefits
and risks, and the patient’s values are important in optimising the
decision (Elwyn 2009a). The decision to participate in an RCT
is a preference sensitive decision. Decision aids have been shown
to be particularly effective for preference sensitive treatment and
screening decisions (Stacey 2014). In addition, existing patient in-
formation leaflets for clinical trials are often lacking in informa-
tion deemed important for good decision making (Gillies 2014a;
Brehaut 2012).
Decision aids may enhance the informed consent process by
improving people’s knowledge and understanding of the deci-
sion to participate and enabling them to reflect on what mat-
ters most to them. Preliminary exploratory studies have shown
that decision aids to inform participation in cancer trials aid un-
derstanding about the trial without increasing patients’ anxiety
(Juraskova 2008; Sundaresan 2011). Another study showed that
explicit values clarification techniques resulted in potential trial
participants evaluating more information in accordance with per-
sonal values, and exhibiting less decisional conflict than the con-
trol group (Abhyankar 2011). These studies provide some ev-
idence that decision aids could be useful in this context. Bet-
ter informed participants may be more likely to make improved
decisions (whether consent or refusal) about trial participation
(Juraskova 2008; Sundaresan 2011), and be more aware of the
expectations on them as a trial participant throughout the study.
Research regulatory guidelines refer to informed consent within
clinical trials as a process (ICH GCP 1996), yet many efforts to
improve the informed consent process to date have focused on im-
proving the information delivery at the point of a decision about
participation. The decision to participate in a clinical trial extends
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beyond the signing of the consent form and continues through-
out the duration of the trial. Often this continued consent is im-
plied by a participant adhering to the trial protocol’s follow-up
procedures, yet this is not always driven by an informed choice at
the outset (Flory 2004; Nishimura 2013). It could be hypothe-
sised that a good decision about trial participation may also result
in some instances in participants completing all trial follow-up
and thus improving retention rates. Decision aids are designed to
support the process that surrounds decision making, and in some
cases may provide ongoing support by acting as a point of refer-
ence for people to refer back to. Therefore, they may also provide
ongoing support for people throughout the decision making pro-
cess when considering clinical trial participation. As such, other
models to improve decision making at the point of participation
are being considered by researchers (Juraskova 2008; Sundaresan
2011; Brehaut 2010; Gillies 2012b).
A tension exists in clinical trials between ensuring potential par-
ticipants are adequately informed, and ensuring that recruitment
and retention are maximised. The evidence on whether informed-
ness is correlated with recruitment is equivocal, but it could be
hypothesised as both a positive or a negative relationship (Flory
2004; Nishimura 2013). The use of decision aids in this con-
text may result in reduced rates of participation for some trials,
as evidence suggests similar interventions promote more conser-
vative decisions for treatment or screening (Stacey 2014). This
may be considered a negative outcome as it could result in trials
taking longer to recruit their desired sample size, and impact on
cost and time to report, which may mean that implementation of
more effective interventions takes longer. However, inadequately
informed participation in a clinical trial may result in participants
dropping out of the trial at a later stage, or worse, participating
in a trial that they might not have chosen had they been better
prepared for the trial decision. Therefore, both outcomes of par-
ticipation and withdrawal could be beneficial or harmful to a par-
ticipant, depending on the specific trial.
Why it is important to do this review
Whilst use of decision aids within a trial context is relatively novel,
the decision support literature is more mature, with international
standards on best practice for use of decision aids (Elwyn 2006).
Furthermore, there is now increased discussion in the ethics liter-
ature about the outcome of consent for research in the face of in-
creasing regulatory requirements. Consideration is being given to
other models for informed consent for research, of which decision
aids are one. Therefore, it is timely to review these interventions
in this context.
O B J E C T I V E S
To assess the effects of decision aids compared with no interven-
tion, usual care, alternative interventions or a combination of these
in people making decisions about participation in RCTs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs and quasi-RCTs of decision aids (i.e. decision aid trials) for
informed consent for participation in a parent RCT were eligible
for inclusion. We used the terms decision aid trial to refer to the
subsidiary nested studies that were the focus of this review, and
parent trial to refer to the (often clinically focused) clinical trial in
which they are set. The decision may relate to participating in a
real or hypothetical parent trial. We investigated studies in which
the decision to participate in the trial was a hypothetical decision,
so as to provide a comparison between real and hypothetical de-
cisions in this context. Quasi-RCTs were defined as trials where
randomisation was attempted but subject to potential manipula-
tion or confounding, for example using day of week, date of birth
or sequence of entry into trial.
Types of participants
We included potential clinical trial participants, or guardians of
or proxy decision makers for potential trial participants. The term
guardian in this reviewwas used tomeanparents or other guardians
acting on behalf of their children, and guardians of adults who
were unable to consent for themselves. There were no restrictions
by age, gender, ethnicity or health condition of participants.
Types of interventions
Adhering to our protocol (Gillies 2012a), included studies eval-
uated the use of decision aids in the informed consent process
for clinical trials. Decision aids may vary in the type of support
they provide and their specific aims. However, in general they are
tools designed to prepare patients to participate in making specific
and deliberative informed choices about their health care, includ-
ing participation in clinical trials. These decision aids differ from
standard patient information leaflets used in trial contexts, as in
addition to providing evidence-based information about a health
condition and identifying the options and outcomes, associated
benefits, harms, probabilities, and scientific uncertainties, they:
1. help potential RCT participants to identify the values-
sensitive nature of the decision and to clarify, either implicitly or
explicitly, the value they place on the benefits, harms, and
scientific uncertainties;
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2. provide structured guidance in the steps of decision
making; and
3. assist potential RCT participants in communicating about
the decision and their values with others involved (e.g. clinician,
family, friends) (Stacey 2014).
We assessed all interventions from included studies for inclusion
using the IPDASi (Elwyn 2009b). Two authors independently as-
sessed the content of interventions from included studies using the
IPDASi. The authors discussed their results and, if required, a third
author repeated the process to enable consensus to be reached.
The following interventions were excluded from this review:
• decision aids about screening or treatment decisions that
were not set within the context of making a decision about
participating in a parent RCT;
• any interventions that were not decision aids (as
determined by the IPDASi) that aimed to enhance the informed
consent process;
• any interventions designed only to improve communication
(i.e. not focus on the decision process) about trial participation
between health professionals and patients;
• studies that did not meet the minimum criteria for the
intervention to be defined as a decision aid (Elwyn 2009b).
Included studies compared an intervention to: no intervention;
standard information (usual care); alternative interventions (an
adapted version of the intervention, such as a more concise version
of the comparator intervention, or a change in mode of delivery
(audio versus paper)); or a combination of these.
Types of outcome measures
In line with previously published reviews of treatment and screen-
ing decision aids, and reviews of information considered impor-
tant for participation in RCTs (Flory 2004; Synnot 2014 Stacey
2014), we considered the outcomes listed below as important.
We also included any relevant studies thatmet the inclusion criteria
but that included outcomes other than those specified.
Primary outcomes
1. Evaluation of informed choice
• Knowledge or understanding;
• Accurate risk perception;
• Values-based decision;
• Recognition that a decision needs to be made;
• Ability to identify features of options that matter most to
individuals;
• Involvement in decision.
2. Decision-making process measures
• Decisional conflict: personal uncertainty about which
course of action to take when faced with a choice between
competing options. Conflict can be measured using the Decision
Conflict Scale (DCS) and is most often measured at the point of
decision making i.e. contemporaneously (O’Connor 1995);
• Decision regret: healthcare decisions that result in bad
outcomes can lead to regret, which can subsequently affect
decision making. Regret can be measured using the Decision
Regret Scale and is most often measured after a decision has been
made i.e. retrospectively (Brehaut 2003).
Secondary outcomes
We collected data on the following secondary outcomes relating
to the parent RCT that people were being recruited to:
• Participation (willingness to participate, or participation
rate);
• Attrition.
Other secondary outcomes related to the decision support RCT
were:
• Anxiety;
• Cost of intervention;
• Patient-recruiter communication.
Search methods for identification of studies
Electronic searches
In March 2015 we searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL);
• The Cochrane Library, March 2015);
• MEDLINE (OvidSP) (1950 to March Week 1 2015);
• EMBASE (OvidSP) (1980 to 2015 Week 09);
• PsycINFO (OvidSP) (1806 to 9 March 2015);
• ASSIA (ProQuest) (1987 to 9 March 2015).
The strategies for each of the databases are presented in Appendix
1. There were no language or date restrictions.
To identify ongoing clinical trials, the following registers were also
searched:
• WHO International Clinical Trials Registry Platform
(ICTRP) (http://apps.who.int/trialsearch/);
• ClinicalTrials.gov;
• ISRCTN Register (http://www.controlled-trials.com/isrctn/
).
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Searching other resources
Grey literature
We searched grey literature using ProQuest Dissertations to access
digital dissertations and theses that were relevant to this review.
Reference lists
We searched reference lists of included studies and relevant review
articles.
Handsearching
We handsearched journals that frequently publish articles on deci-
sion aids, such asMedical Decision Making,Health Expectations and
Patient Education and Counseling, along with specific health ser-
vices research journals such as Trials; Clinical Trials; BMC Health
Services Research; BMC Medical Research Methodology; Research
Ethics; American Journal of Bioethics and Journal of Empirical Re-
search on Human Research Ethics.
Correspondence
We contacted the shared decision making community through
social media to identify any additional new or ongoing studies.
We also contacted Directors of UKCRC Clinical Trials Units to
identify any new or ongoing studies. In addition, when authors of
included studies were contacted for further details of interventions
we also asked if they were aware of any additional studies in this
area.No studies were identified through these routes. Two ongoing
studies (see Characteristics of ongoing studies) were identified.
Data collection and analysis
Selection of studies
Stage 1
We conducted searches for relevant studies on the prespecified
databases. We combined results and removed duplicates.
Stage 2
All review authors independently screened titles and abstracts of
identified articles for relevance. Sets of abstracts were created such
that all identified articles were screened by two authors.
Stage 3
Four authors (KG, ZS, SC, JB) further assessed the set of poten-
tially relevant abstracts identified from the initial full screen and
discussed any disagreements. We retrieved full text copies for all
potentially relevant papers, including those where the description
(usually relating to the intervention) was insufficient to make a
decision about inclusion.
Stage 4
Two authors independently screened the full text articles against
eligibility criteria for inclusion or exclusion. Where interven-
tions were deemed eligible, authors assessed interventions using
the IPDASi, as per the process outlined by Elwyn 2009b and
Joseph-Williams 2013. Two review authors discussed results, and
if required, a third researcher repeated the process to enable con-
sensus to be reached. See Characteristics of excluded studies for
details on reasons for exclusion of full text articles.
We provided citation details and any available information about
ongoing studies (see Characteristics of ongoing studies), and col-
lated and reported details of duplicate publications, so that each
study was the unit of interest in the review. We reported the
screening and selection process in an adapted PRISMA flow chart
(Liberati 2009); see Figure 1.
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Figure 1. Study flow diagram
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Data extraction and management
Four authors (KG, ZS, SC, JB) independently extracted data from
each included study. Any discrepancies were resolved by discus-
sion to reach consensus, or through consultation with a third au-
thor where necessary. We based data extraction categories on the
Cochrane Consumers and Communication Group Data Extrac-
tion Template but supplemented those with additional important
categories for this context (relating to parent RCT), and included
the following categories: features of the parent RCT; decision sup-
port RCT methods; intervention and comparator features; out-
comes; data and results; conclusions and limitations.
All extracted data were entered into RevMan (RevMan 5.3) by one
review author, and checked for accuracy against the data extraction
sheets by a second review author working independently.
Information is presented in Characteristics of included studies.
When more than one primary outcome was available from an in-
cluded study (e.g. when multiple outcomes contribute to a single
category, such as knowledge and understanding) we used the fol-
lowing process for selecting a single outcome (Brennan 2009):
1. Select the primary outcome that was identified by the
authors of the included study;
2. When no primary outcome was identified, select the
outcome specified in the sample size calculation;
3. If there were no sample size calculations, we ranked the
effect estimates and used the median effect estimate.
Assessment of risk of bias in included studies
We assessed and reported the risk of bias of included studies in
accordance with the Cochrane Handbook (Higgins 2011) and
the guidelines of the Cochrane Consumers and Communication
Group (Ryan 2011), which recommends reporting the following
items for RCTs based on the risk of bias tool:
• random sequence generation;
• allocation concealment;
• blinding (participants, personnel);
• blinding (outcome assessors);
• completeness of outcome data;
• selective outcome reporting;
• baseline comparability (for quasi-randomised studies).
Four authors (KG, ZS, SC, JB) independently assessed risk of
bias of the included study, rating each of the domains as high
risk, unclear or low risk (as detailed in the Cochrane Handbook),
with any disagreements being resolved through discussion and
consensus.
Our assessment is reported in Risk of bias in included studies,
along with a justification for the ratings given. Whilst we had
planned to consider the results from the risk of bias assessment of
included studies when performing and presenting analyses, and
restricting the primary analysis to studies at low risk of bias, this
was not appropriate due to inclusion of a small number of studies
in the analysis.
The results of the risk of bias assessment have been incorporated
into the review through standard tables, and systematic narrative
description and commentary about each of the elements, leading
to an overall assessment the risk of bias of included studies and a
judgement about the internal validity of the reviews results.
Studies were deemed to be at the highest risk of bias if they are
scored as at high or unclear risk of bias for either the sequence
generation or allocation concealment domains, based on growing
empirical evidence that these factors are particularly important
potential sources of bias (Higgins 2011).
Measures of treatment effect
A meta-analysis was conducted. It should be highlighted that
whilst only one study was included, it reported data from two
decision aid trials (Juraskova 2014 (Prevention); Juraskova 2014
(DCIS)). The data were presented separately in the original pub-
lication (patients were being recruited to two separate parent tri-
als and as such generated two separate decision aid trials) but it
was felt to be appropriate to pool the results for this review (see
justification in Included studies). The included study had several
continuous outcomes. Therefore, we analysed data based on the
mean, standard deviation (SD) and number of people assessed for
both the intervention and comparison groups to calculate a mean
difference (MD), with 95% confidence interval (CI), between the
post-intervention values of the randomised groups. For dichoto-
mous outcomes we analysed data based on numbers of events and
numbers of people assessed in the intervention and comparison
groups, and used these to calculate a risk ratio (RR) with 95% CI.
Unit of analysis issues
We analysed both the mean and SD provided in the included
study. We calculated the mean and SD according to the overall
numbers within each arm using established approaches (Higgins
2011).
If cluster-RCTs were included we would have checked for unit-
of-analysis errors. If errors were found, and sufficient information
was available, we would have re-analysed the data using the ap-
propriate unit of analysis, by taking account of the intra-cluster
correlation (ICC). We would have obtained estimates of the ICC
by contacting authors of included studies, or imputing them by
using estimates from external sources. If it was not possible to ob-
tain sufficient information to re-analyse the data we would report
effect estimates and annotate unit-of-analysis error.
11Decision aids for people considering taking part in clinical trials (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dealing with missing data
We contacted study authors to obtain missing data (participant,
outcome, or summary data). For participant data, we analysed
outcomes as reported as no information on intention-to-treat was
available within the study report or was available from authors
of the study. We reported on the levels of loss to follow-up and
assessed this as a source of potential bias.
Where possible, missing standard deviations were calculated from
other reported statistics. Specifically, this was the case for percent-
age enrolled and percentage who dropped out. We discussed any
impact of missing data on the findings of the review in the main
text and the Risk of bias in included studies table.
Assessment of heterogeneity
Where studies were considered similar enough (based on consid-
eration of populations and/or interventions) to enable pooling of
data using meta-analysis, we assessed the degree of heterogene-
ity by visual inspection of forest plots. We assessed heterogene-
ity between the decision aid trials from the included study using
the Chi² statistic, to provide evidence of heterogeneity, and the I²
statistic, to quantify the degree of heterogeneity (a Chi² P value
of less than 0.10 or an I² value equal to or more than 50% was
considered to indicate substantial heterogeneity).
Where heterogeneity was present in pooled effect estimates we
planned to explore possible reasons for variability by conducting
subgroup analysis.
We planned that where we detected substantial clinical, method-
ological or statistical heterogeneity across included studies we
would not report pooled results frommeta-analysis but instead use
a narrative approach to data synthesis. In this event, we planned
to attempt to explore possible clinical or methodological reasons
for this variation by grouping studies that were similar in terms of
populations, interventions and methodological differences (such
as real or hypothetical decision) to explore differences in interven-
tion effects. However, the small number of included studies meant
that subgroup analyses could not be conducted.
Assessment of reporting biases
We planned to assess reporting bias qualitatively based on the
characteristics of the included studies (such as if only small studies
indicating positive findings were identified for inclusion), and if
information that we could obtain from contacting experts and
authors of studies suggested that there were relevant unpublished
studies.
If we had identified sufficient studies (at least 10) for inclusion we
would have constructed a funnel plot to investigate small study
effects, which may have indicated the presence of publication bias.
We would have formally tested for funnel plot asymmetry, with
the choice of test made based on advice in Higgins 2011, and
bearing in mind that there may be several reasons for funnel plot
asymmetry when interpreting the results.
However, we could not conduct assessment of reporting bias due
to only one study being eligible for inclusion, but this was not
deemed to be a considerable risk.
Data synthesis
There was only one included study, presented as two separate
decision aid trials, with no difference in the comparator groups.
In future updates we will analyse studies according to comparison
groups, specifically:
• Decision aid versus no intervention;
• Decision aid versus usual practice;
• Decision aid versus alternative interventions.
We conducted a meta-analysis where trial data were sufficiently
similar (in intervention, outcome measure, length of follow-up
and type of analysis). We present results for each of the reported
outcomes, organised by the comparison intervention.
Due to the variability in both the populations and interventions
of the included study, we used a random-effects model for meta-
analysis.
We did not use narrative synthesis, but would do in future updates
where studies are not suitable for meta-analysis. For example, if
mean and SD cannot be extracted for continuous outcomes, we
will present the summary statistic and measure of variance at fol-
low-up available in the text of the included studies, and if there
is more than one study, we will present these data in additional
tables.
Subgroup analysis and investigation of heterogeneity
We found there were insufficient data to conduct subgroup anal-
ysis. In future updates we will conduct subgroup analyses where
data are available, according to:
• Decision regarding trial participation: real versus
hypothetical;
• Mode of delivery (e.g. video/computer versus audio/
pamphlet). Mode of delivery may make a difference to the
effectiveness of decision support tools. For example, an RCT that
compared a paper-based decision aid versus an Internet-based
version for prostatic specific antigen (PSA) screening showed that
participants randomised to the Internet version had different
levels of screening uptake (Evans 2010). This may translate to
different modes of delivery affecting uptake to clinical trials, and
as such, this would be explored in subgroup analysis;
• Context of intervention delivery. Context of intervention
delivery is also linked to mode of delivery but may impact more
on cost effectiveness of the intervention (Belkora 2010).
Moreover, context has been proposed by other researchers in the
decision aid literature as being an important variable for
consideration during decision aid development, delivery and
evaluation (Elwyn 2010a, Thomson 2010). The following
contexts will be explored in subgroup analysis:
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◦ used in face-to-face clinical encounters;
◦ used independently from the clinical encounter;
• Quality of intervention as measured by the IPDASi
(dichotomised by score: 0 to 50 and 51 to 100);
• Participant characteristics. Various participant
characteristics may have an impact on the effectiveness of
decision aids. Age and gender have been shown to have a
significant effect on participants’ perception of the factors that
determine decision processes (Sanz de Acedo Lizararraga 2007).
Also, decision aids designed specifically for use with low level
literacy groups have been shown to be effective in supporting
informed choices and greater participant involvement in some
screening decisions (Smith 2010). As such, the following would
be explored in subgroup analysis:
◦ age (categorised as under 18, 18 to 65, over 65 years);
◦ gender (male versus female);
◦ education (no formal education and higher education).
Sensitivity analysis
Because there was only one included study, which included two
methodologically similar decision aid trials which did not fulfil
the high/unclear risk of bias requirements outlined below, we were
unable to conduct a sensitivity analysis. In future updates, we will
group studies according to whether they are at high/unclear risk
of bias or low risk of bias to investigate the effect of trial quality
on meta-analysis results. We will categorise studies at overall high
or unclear risk of bias if rated as being at high or unclear in one or
more of the following domains: sequence generation, allocation
concealment or selective outcome reporting. The remaining stud-
ies would be considered at low risk of bias. These three domains
were selected because limited, but growing, empirical evidence
from methodological studies suggests they can most strongly in-
fluence intervention effect estimates (Higgins 2011). We will ex-
clude studies at high/unclear risk of bias in a sensitivity analysis to
determine whether the risk of bias influenced review findings.
Assessing the overall quality of the evidence
We used the GRADE approach to make assessments of the overall
quality of the evidence for each outcome on each of the following
domains: risk of bias, inconsistency, imprecision, indirectness and
publication bias. We downgraded a starting rating of high quality
evidence by one level for serious concerns (or by two levels for very
serious concerns) about each of these domains. We considered the
impact of the following factors (as specified by Higgins 2011) on
the quality of the evidence:
• risk of bias: limitations in the design (e.g. lack of allocation
concealment, lack of blinding, large loss to follow up, etc.) and
implementation of included studies;
• inconsistency: unexplained heterogeneity or inconsistency
of results;
• imprecision: imprecise results, that is, wide confidence
intervals generated from small samples and few events;
• indirectness: where the included evidence is from indirect
populations, interventions, controls or outcomes;
• publication bias: probability of publication bias.
Each quality domain was assessed and where there was a low risk
of bias the quality rating remained high, an unclear risk of bias
resulted in a downgrading of the evidence by one level and a high
risk of bias by two levels for very serious concerns. The judgements
regardingdowngradingwere guidedbyTable12.2d in theCochrane
Handbook (Higgins 2011).
Two authors independently assessed the quality of the evidence as
implemented and described in the GRADEprofiler (GRADEpro)
software (Schünemann 2011).
Summary of findings table
We used the GRADE criteria to evaluate quality of evidence us-
ing GRADEprofiler (GRADEPro) software (Schünemann 2011)
before presenting data in a summary of findings table and taking
into account the quality of the evidence, magnitude of the effect
of the intervention and the sum of the available data on the pri-
mary rather than main outcomes, as outlined in Types of outcome
measures. We presented outcomes in the summary of findings ta-
ble in terms of:
1. Evaluation of informed choice (knowledge; accurate risk
perception; values-based decision; recognition that a decision
needs to be made; involvement in decision); and
2. Decision making process measures (decisional conflict and
decisional regret). We provide a source and rationale for each
assumed risk cited in the table. Because GRADE allows only
seven outcomes to be listed in the summary of findings table, a
primary outcome (ability to identify features of options that
matter most to individuals) was not included. Our justification
was that we felt this outcome may overlap with ’values based
decision’ outcome. It should be noted that this was a post-hoc
decision.
Consumer participation
As part of a larger project (led by KG), a survey and interviews with
RCT stakeholders, which included potential participants, clini-
cians, and trialists, was conducted to determine key information
to include in, and perceptions of, a decision aid to inform RCT
participation (Gillies 2013; Gillies 2014b). This stakeholder con-
sultation stage helped to identify consumer-relevant content of
these interventions and relevant outcomes, which mapped on to
the decision aids identified in this review. The first author (KG) is
leading additional work to identify a core outcome set for evalua-
tion of interventions to improve informed consent (Gillies 2014e).
This work will inform future updates of this review.
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R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; and Characteristics of ongoing studies.
Results of the search
We conducted electronic searches in March 2015 and identi-
fied 13,122 references and we identified six references from other
sources. Following de-duplication, we screened 9505 records for
eligible studies. From the initial screen, we further assessed 32 ab-
stracts for eligibility, with and requested full text for 24 records
to provide more detail about interventions under investigation.
Of these 24 full text papers, we assessed six for inclusion us-
ing the IPDASi to assess the reported intervention (see Types
of interventions) and subsequently excluded five of these (see
Characteristics of excluded studies and Excluded studies) . There
was one paper that reported two decision aid trials which met the
inclusion criteria (Juraskova 2014 (Prevention); Juraskova 2014
(DCIS)). Figure 1 illustrates the searching and screening process.
Included studies
We included one study that presented data from 290 women who
participated in two separate decision aid trials (Juraskova 2014
(DCIS); Juraskova 2014 (Prevention)). These women were con-
sidering participation in one of two parent RCTs - either the Inter-
national Breast Cancer Intervention Study II (IBIS-II) Prevention
Trial (a primary prevention trial comparing anastrozole or placebo
in postmenopausal women at high risk of breast cancer) or the
IBIS-II Ductal Carcinoma in Situ (DCIS) Trial (a treatment trial
comparing anastrozole or tamoxifen in postmenopausal women
who had previous surgery for DCIS) (Cuzick 2008). The authors
of the decision aid trials reported the nested setting as being within
two separate parent RCTs and presented the data analysis sepa-
rately for each decision aid trial. Outcomes measured (both con-
tent and timing) were identical across both decision aid trials. For
the purposes of this review we have also treated the decision aid
trials as two individual trials. This is for several reasons, not least
because the study authors treated the decision aid trials as two
separate clinical trials, but in addition:
• the parent trials to which participants were being recruited
were testing different clinical interventions in different
populations and addressed different decisions about trial
participation;
• the recruitment methods for each decision aid trial differed
(e.g. the parent primary prevention trial identified women using
media advertisements who were telephoned by clinical staff and
invited to join the relevant decision aid trial; whereas women
eligible for the parent treatment DCIS trial were approached
directly by their surgeon and invited to join the relevant decision
aid trial);
• the eligible populations included in the decision aid trials
differed;
• the decision aid interventions tested in each decision aid
trial differed.
For clarity, throughout the remainder of this review when referring
to the decision aid trials collectively we refer to them as the decision
aid trials and separately as:
• prevention decision aid trial when referring to the nested
decision aid trial that recruited women to the IBIS-II parent
primary prevention trial;
and
• DCIS decision aid trial when referring to the nested
decision aid trial that recruited women to the IBIS-II parent
DCIS treatment trial.
Study design
Both decision aid trials nested in the included study were two-arm
parallel RCTs.
Sample size
The randomised sample for the DCIS decision aid trial was 67
and 223 for the prevention decision aid trial. In total 290 people
participated in the included study.
Setting
Participants were recruited via the parent trial sites which were
largely based in high-income countries (Australia, New Zealand,
and United Kingdom).
Participants
Thewomenwhoparticipated in the decision aid trials were eligible
for the parent trial, the IBIS-II, specifically, either the Prevention
or DCIS trials. The population of participants recruited to both
decision aid trials were very similar and included postmenopausal
women with a mean age of 59 years. As per the parent trial, the
recruitment approach differed by decision aid trial; the prevention
decision aid trial women were invited by clinical staff over the
telephone and the DCIS decision aid trial women were invited by
their surgeon.
It was explicit in the report of the included study that the inter-
ventions in both decision aid trials were conducted in English,
with most (94%) women specifying English as their spoken lan-
guage. Further information about the participants is presented in
Characteristics of included studies.
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Interventions
The included study reported two decision aid trials that were both
two-arm parallel RCTs of a single comparison: decision aids versus
standard informed consent procedures. The interventions in the
decision aid trials were paper-based decision aids. These were com-
pared to standard informed consent procedures, which included a
patient information leaflet, but no further details about the con-
trol intervention were available.
Two decision aids were tested, one specific to each of the clin-
ical trials (one each for the prevention and DCIS decision aids
trials). The delivery of the interventions was not clear but likely
was without direct supervision and may have differed by decision
aid trial (the prevention decision aid trial participants may have
received the decision aid by post and the DCIS decision aid trial
participants in a face-to-face setting). The decision aid booklets
were designed to include evidence-based representation of breast
cancer risk, the parent trial rationale, explanation of management
options available on and off the trial, a comparison of the risks and
benefits of each option, and values clarification worksheets. The
decision aids were designed to meet IPDAS guidelines for content
development.
Outcomes
Primary outcomes
Knowledge and understanding
Evaluation of informed choice
• Knowledge or understanding;
• Accurate risk perception;
• Values-based decision;
• Recognition that a decision needs to be made;
• Ability to identify features of options that matter most to
individuals;
• Involvement in decision.
Decision-making process measures
• Decisional conflict: personal uncertainty about which
course of action to take when faced with a choice between
competing options. Conflict can be measured using the Decision
Conflict Scale (DCS) and is most often measured at the point of
decision making i.e. contemporaneously (O’Connor 1995);
• Decision regret: healthcare decisions that result in bad
outcomes can lead to regret, which can subsequently affect
decision making. Regret can be measured using the Decision
Regret Scale and is most often measured after a decision has been
made i.e. retrospectively (Brehaut 2003).
The included study reported data for three different measures of
knowledge:
• Knowledge of clinical trials (study specific seven item
measure of general trial related knowledge);
• Objective knowledge (assessed using a 12 and 16 item study
specific knowledge scale in the Prevention and DCIS cohorts
respectively); and
• Subjective knowledge (assessed using Part B (14 items
assessing subjective/perceived understanding) of the Quality of
Informed Consent (QuIC) scale (Joffe 2001)).
Knowledge was measured at baseline (post-randomisation after a
trial participation decision had been made - post-decision). As the
decision aid trials did not rank knowledge outcomes, we chose to
include only data collected with a validated tool, i.e. the QuIC
measure of subjective/perceived understanding . This judgement
was based on a hierarchy of measures which assumed validated
objective measures to be superior to study-specific non-validated
measures This hierarchical judgement relating to multiple mea-
sures of the same outcome was a post-hoc decision made during
the review process.
Decisional conflict was measured at baseline in the decision aid
trials using the Decisional Conflict Scale (DCS), which contains
16 items that measure the amount of uncertainty an individual has
about a course of action (O’Connor 1995). This was the primary
outcome for the decision aid trials.
Decision regret was measured at three months using the Deci-
sional Regret Scale, a five-item scale with good internal consis-
tency that measures regret associated with a decision made in the
past (Brehaut 2003).
The decision aid trials did not report data for the followingprimary
outcomes:
• accurate risk perception;
• values-based decision;
or if potential participants had:
• recognised that a decision needed to be made;
• ability to identify features of options that matter most to
individuals;
• involvement in decision making.
Secondary outcomes
Data on secondary outcomes relating to the decision about entry
into the parent trial were collected in the decision aid trials:
• participation (presented as both intention to participate
and percentage actually enrolled in IBIS-II (parent trial), we
included data captured using the second measure (% enrolled) as
it is a more definitive measure of participation);
• attrition (as percentage who dropped out from IBIS-II
(parent trial)); and
• anxiety (measured at baseline using a six-item short form of
the State-Trait Anxiety Inventory (STAI-S) scale (Marteau
1992)).
No data were reported for:
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• cost of intervention;
• patient-recruiter communication.
Consumer involvement
Although the decision aid trials did not report consumer involve-
ment, an earlier linked publication described consumer involve-
ment in the development of the decision aids tested in the preven-
tion decision aid trial (Juraskova 2008).
Funding sources
The included study was supported by Susan G. Komen for the
Cure (grant number BCTR0503961) and discretionary funding
from theBreastCancer Institute of Australia, which is the fundrais-
ing and education department of the Australia and New Zealand
Breast Cancer Trials Group (ANZBCTG; no grant number).
Excluded studies
We excluded 23 studies following assessment of full text articles.
The reasons for excluding papers that went through full text review
are outlined in the Characteristics of excluded studies. There were
four reasons that contributed to studies being excluded. The most
prevalent reason was the intervention not being a decision aid
(determined by assessment of qualifying items using IPDASi) (n
= 8), followed by the intervention not being a decision aid for trial
participation (i.e. a decision aid for treatment or screening) (n = 5),
or the intervention ineligibility was decided based on published
report and/or information present in a similar Cochrane review
(Synnot 2014) and/or discussion with study author (n = 7) and
ineligible study design (n = 3).
Risk of bias in included studies
We assessed the two decision aid trials from one included study
for risk of bias and assessed them to be at moderate to high risk
of bias overall (Risk of bias in included studies; Figure 2; Figure
3). The included study provided insufficient information in the
published paper about some aspects of study design and conduct
and was assessed as unclear on a number of domains. Risk of bias
was highest in the domains relating to blinding of participants
and outcome assessors which reflects the inherent difficulties of
blinding in trials testing information provision in this context.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
As all outcomes (for which data were identified) included pooled
data from RCTs only, the evidence was downgraded from high to
lowquality for risk of bias, indirectness, imprecision or publication
bias for all outcomes with the exception of attrition, which also
included downgrading of the evidence (from high to low quality
for inconsistency).
Allocation
Random sequence generation
The authors of the included study reported using a randomisation
sequence that was generated using a web-based random number
generator (www.randomizer.org) with randomisation performed
in blocks of 10 according to centre and was rated as low risk of
bias.
Allocation concealment
A pre-randomised, sequentially numbered system using sealed en-
velopes was reported by the authors and assessed as being adequate
allocation concealment at low risk of bias.
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Blinding
Most outcomes measured in RCTs of this type capture self-re-
ported outcomes often relating to knowledge and other aspects
of decision making. As the participants are not blinded to their
allocation, and they are the outcome assessors, it is indeed difficult
for investigators to blind outcome assessment. Of all outcomes re-
ported, only two could be measured objectively: actual enrolment
and drop out from the parent RCT. The included study was as-
sessed at being of high risk of bias for blinding of both participants
and outcome assessment.
Incomplete outcome data
With regard to completeness of outcome data, the authors re-
ported that 66 participants (23% of those randomised) were not
included in the analysis (a post-randomisation decision) due to
previous participation in a clinical trial which they hypothesise
may have resulted in ceiling effects for several of the measures. In
addition, data were only reported on 146 of the 290 randomised
(50%) participants, bringing into question whether the partici-
pants for whom data were missing differed from those who did
not. However, the authors reported that there were no differences
in rates or reasons for dropout across the arms.
Selective reporting
The study did not refer to a published protocol against which
the published report could be assessed. Risk of bias was therefore
assessed to be unclear. However, of those outcomes listed in the
methods all were presented in the results.
Other potential sources of bias
There were recruitment problems reported for the DCIS decision
aid trial, which resulted in that trial being underpowered. Each of
the reported decision aid trials required a sample size of 128 (64
per arm) to detect an effect size of 0.5 with 80% power. The DCIS
decision aid trial randomised 67 participants and analysed data
on 24, and the Prevention decision aid trial randomised 223 and
analysed data on 95 participants (see Incomplete outcome data
(attrition bias) for more information).
Effects of interventions
See: Summary of findings for the main comparison Decision
aids for informed consent versus standard informed consent for
people considering taking part in clinical trials
Decision aid for informed consent versus standard
informed consent
Primary outcomes
Knowledge
The included study reported three separate measures of knowl-
edge for both decision aid trials (see Included studies). The data
on subjective knowledge was selected for analysis of knowledge
due to the fact that these data were collected using a validated tool
(QuIC; Joffe 2001). The pooled intervention arms from the deci-
sion aid trials highlighted that effects on knowledge are uncertain,
compared with standard informed consent procedures, given the
wide confidence intervals and small sample sizes (MD 1.68, 95%
CI -1.91 to 5.26; Analysis 1.1). There was no indication of het-
erogeneity in these results. The quality of the evidence was rated
as very low due to risk of bias (a lack of blinding and incomplete
outcome data), indirectness of populations studied, and the wide
confidence intervals around the effect estimate, with at least 25%
variation in both control and intervention groups.
Decision conflict
Pooling the decision conflict scores (a measure of uncertainty) for
both decision aid trials also showed uncertain effects on decision
conflict, compared with standard informed consent procedures,
due to the wide confidence intervals and small sample size (MD
3.47, 95% CI -1.51 to 8.45; Analysis 1.2). Again there was no
indication of heterogeneity in the results for this outcome.
As with the knowledge outcome, the quality of the evidence for
decisional conflict was downgraded from high to very low due
to risk of bias (a lack of blinding and incomplete outcome data),
indirectness of populations studied, and the wide confidence in-
tervals around the effect estimate, with at least 25% variation in
both control and intervention groups.
Decision regret
The pooled intervention arms showed evidence of a small effect
in favour of the decision aids on decisional regret, compared with
standard consent procedures, when combining the results from
both decision aid trials (MD -5.53, 95% CI -10.29 to -0.76;
Analysis 1.3), again with no evidence of heterogeneity in the re-
sults. However, the data were from two relatively small decision
aid trials, with the weighting of the evidence in favour of the larger
prevention decision aid trial which had a significant effect esti-
mate.
The quality of the evidence was rated as very low due to risk of bias
(a lack of blinding and incomplete outcome data), indirectness
of populations studied, and the confidence intervals around the
effect estimate being relatively large in relation to the effect size.
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Secondary outcomes
Participation
Actual enrolment was measured as a percentage of those who par-
ticipated in the parent trial. Following pooling of results across
both decision aid trials there was uncertainty around any effect
on enrolment, compared with standard consent procedures (RR
1.06, 95%CI 0.76 to 1.48; Analysis 1.4). There was no indication
of heterogeneity in the results; but the quality of the evidence was
rated as very low due to risk of bias (a lack of blinding and in-
complete outcome data), indirectness of populations studied, and
wide confidence intervals around the effect estimate.
Attrition
Attrition was reported as the number of participants who dropped
out of the parent RCT who were enrolled in the decision aid
trial. Results from the decision aid trials were pooled and showed
uncertain effects on attrition, compared with standard consent
procedures (RR 1.55, 95% CI 0.51 to 4.68; Analysis 1.5). As for
other outcomes, there was no evidence of heterogeneity in this
result; but the quality of the evidence was rated as very low due
to risk of bias (a lack of blinding and incomplete outcome data),
indirectness of populations studied, and wide confidence intervals
around the effect estimate, with at least 25%variation of the events
in both the control and intervention groups.
Anxiety
Uncertain effects were observed on anxiety when the results from
the decision aid trials were pooled (MD -2.38, 95% CI -10.65 to
5.90; Analysis 1.6). There was substantial heterogeneity (I² = 78%)
in this result, with both positive and negative effects on anxiety for
the two different trials (but with confidence intervals that passed
through the line of no effect). The quality of the evidence was
again rated as very low due to risk of bias (a lack of blinding and
incomplete outcome data), indirectness of populations studied,
and wide confidence intervals around the effect estimate.
No data were reported for the following prespecified primary out-
comes: accurate risk perception; values based decision; recognition
that a decision needs to be made; ability to identify features of op-
tions that matter most to individuals; or involvement in decision;
or secondary outcomes of intervention cost or patient-recruiter
communication.
D I S C U S S I O N
Summary of main results
We identified one study reporting two decision aid trials re-
cruiting with a total of 290 participants that investigated the
effectiveness of decision aids (compared to standard informa-
tion) in the informed consent process for RCTs (Juraskova 2014
(Prevention); Juraskova 2014 (DCIS)). This study report included
postmenopausal women being recruited to one of two decision
aid trials, each nested within the context of a larger parent RCT,
either the IBIS-II Prevention Trial (a prevention RCT comparing
anastrozole or placebo in postmenopausal women at high risk of
breast cancer) or the IBIS-II DCIS Trial (a treatment RCT com-
paring anastrozole or tamoxifen in postmenopausal women who
had previous surgery for DCIS) (Cuzick 2008).
When the results from each of the individual decision aid trials
were pooled, there was considerable uncertainty about the effects
of the intervention, comparedwith standard information, onmost
of the outcomes reported: knowledge, decisional conflict, anxi-
ety, trial participation and trial attrition, due to wide confidence
intervals and small sample sizes. There was very low quality evi-
dence that decision aids may decrease decisional regret to a small
degree (i.e. less regret amongst those exposed to the intervention),
when compared with standard information. Additional outcomes
we identified as being of potential importance were not reported.
These included accurate expectations about benefits and harms;
reaching choices that are consistent with personal values; recog-
nition that a decision needs to be made; and involvement in the
decision.
Overall completeness and applicability of
evidence
Population and setting
Our conclusions were limited because only one study was iden-
tified (albeit including two decision aid trials) that met our in-
clusion criteria. The interventions investigated were delivered in
high income countries tomainly English speakingpostmenopausal
women who had existing breast cancer or who were at high risk
of developing breast cancer.
Control intervention
It was noteworthy that the included study compared decision aids
with existing, written, consent documents and the intervention
group received both. Other reviews of informed consent interven-
tions (for trials (Synnot 2014) and treatment (Kinnersley 2013))
have highlighted the potential for both the intervention and con-
trol groups to benefit in studies of this type. We believe the re-
sults of the included study to be consistent with this finding for a
number of reasons. Firstly, the authors note that the trial recruiters
involved in the parent trial (IBIS-II) had received communica-
tion skills training, which may have influenced the results of the
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decision aid trials. Moreover, trial recruiters may have changed
their behaviour during the decision aid trials, optimising their in-
formed consent practice. Another potential limitation of the in-
cluded study is the lack of detail about the fidelity of both the
intervention and standard information. In other words, no infor-
mation was recorded about whether the decision aids or the stan-
dard information was in fact read by participants. Trials of this
kind may benefit from process evaluations to explore how trial
processes and interventions are delivered in context.
Study design
Several full reviews (both published and in progress) have inves-
tigated the effectiveness of a variety of interventions in the in-
formed consent process for clinical trials (Flory 2004; Hon 2012;
Nishimura 2013; Synnot 2014).
Whilst some of these studies focus on specific types of interven-
tions (such as audio-visual interventions, Synnot 2014), others
have reviewed all interventions and grouped them accordingly
(Nishimura 2013). Interventions for informed consent vary sig-
nificantly, from simplified consent forms to enhanced discussions
involving directed training for staff (Nishimura 2013). However,
many of these interventions focus more on the structure and con-
tent of the presented information rather than the process of de-
cision making. Therefore, to focus our review we only included
interventions that aimed to support an informed decision making
process and these interventions were defined according to the IP-
DASi (Joseph-Williams 2013). This definition deviates from the
method used in the review of treatment and screening decision
aids, which defined interventions as decision aids if they were “de-
signed to help peoplemake specific and deliberative choices among
options (including the status quo), bymaking the decision explicit
and by providing (at the minimum) a) information on the options
and outcomes relevant to a person’s health status and b) implicit
methods to clarify values” (Stacey 2014). Some of the interven-
tions we excluded from our review (Abhyankar 2011; Meropol
2013; Tait 2010) contained components of decision aids but did
not meet minimum criteria we defined as a requirement for in-
clusion based on those described by the IPDASi (Joseph-Williams
2013). In addition, some of these interventions were treatment
decision aids being used alongside patient information leaflets (i.e.
trial participation was not the index decision); and rather the deci-
sion to have treatment or not was the index decision (Eccles 2013).
Future updates may wish to consider the inclusion of these studies
(and others which may fit the definition used by Stacey 2014 in
specific subgroups comparisons (i.e. values clarification exercises)
or comparisons (i.e. treatment decision aid + patient information
leaflet vs. patient information leaflet). The effect of excluding these
studies on the results of this review is unclear.
Outcomes
As noted by other authors, the assessment and measurement
of outcomes associated with informed consent is problematic
(Kinnersley 2013; Synnot 2014; Nishimura 2013).The hetero-
geneity of outcome measures used to assess knowledge or under-
standing has significant implications for systematic reviews and
meta-analysis of these types of outcome data. There is currently no
standardised validated measure for knowledge or understanding
as an outcome (Nishimura 2013). Neither is there consensus on
whether this is an adequate measure of being informed, and when
it should be measured in relation to the decision. This is an area
requiring further research (Gillies 2012b; Gillies 2014c). We are
currently conducting a systematic review of existing validatedmea-
sures of informed consent, but again many of these measures focus
on knowledge and understanding and are largely assessed through
recall (Gillies 2014d). There has also been debate in the literature
about the adequacy of decisional regret as a measure of the de-
cision making process, both in the context of treatment (Elwyn
2010b) and trial decisions (Gillies 2014c). Some opponents have
argued that regret can be biased by decision outcomes (due to the
timing of outcome measurement i.e. post-decision) and may not
offer a measured representation of the decision process but more
a judgement related to outcomes (Elwyn 2010b).
When considering interventions aimed to improve the decision
making process it is also important to consider outcomes in addi-
tion to knowledge and understanding. Whilst these outcomes are
important building blocks for informed decision making they are
not the only components that can help support patients’ decisions
(Stacey 2014). When determining our specified outcomes for this
review we were informed by the Cochrane review on decision aids
for treatment and screening, which considered decision making
as two components: evaluation of informed choice (encompassing
attributes of the decision and its process); and decision making
process measures (Stacey 2014). Other authors of similar reviews
have also highlighted the need for outcome measures that cap-
ture informed consent “as a unified concept” (Kinnersley 2013)
and that more research is needed to gain consensus on defining
the range of potentially relevant outcomes in this context, not
just from a researcher’s perspective, but also from patients (Synnot
2014). We are conducting research with a range of stakeholders
(including patients) aimed to develop a core outcome set for the
evaluation of interventions intended to improve informed consent
for clinical trials (Gillies 2014e).
Lastly, process measures associated with delivery of the interven-
tion were prespecified in this review (e.g. patient-recruiter com-
munication and costs of intervention) but not reported in the in-
cluded study. Data from process measures would be helpful to
make decisions about implementation of decision aids, especially
where the evidence is equivocal.
Quality of the evidence
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The evidence for each reported outcome was assessed as very low
quality according to the GRADE assessment. This was primarily
due to the small sample sizes and wide confidence intervals, which
in all but one case, crossed the line of no effect. This significant
uncertainty surrounding most of the outcomes, together with a
lack of data for many other potentially important outcomes, sup-
ports the case for additional research.
When assessing the standard Cochrane risk of bias domains it was
noted that the included study did not provide sufficient informa-
tion about study design and conduct, and as such, a number of
domains were judged as unclear. Risk of bias was highest in do-
mains relating to blinding of participants and outcome assessors
which reflects the inherent difficulties of blinding in trials that test
information provision.
Synnot 2014 and others suggest that in addition to the standard
Cochrane risk of bias domains, consumer health information in-
terventions might also consider whether interventions are devel-
oped using a theoretical framework and if consumers are involved
in intervention development (Sheridan 2011; Synnot 2014). The
authors of the included study in this review published an earlier
paper that reports the piloting of the interventions tested in the
decision aid trials (Juraskova 2008). They reported that they in-
cluded consumers in the development of the intervention and it
was informed by the theoretically-based Ottawa decision support
framework (O’Connor 1998). Future updates of this review may
wish to consider subgroup analyses based on presence and absence
of consumer involvement, and theoretically informed versus the-
oretical decision aids.
Potential biases in the review process
We applied standard Cochrane review methodology with the aim
of minimising bias. At least two authors were involved in all criti-
cal stages of the review process. Where appropriate, we contacted
authors of included and potentially eligible studies, largely to de-
termine eligibility of interventions, and access additional data to
support the published report. Several potentially eligible studies
were excluded based on inability of the study authors to provide
copies of the original interventions tested.However, through email
discussion it often became apparent that the reported interven-
tions were not formal decision aids or could be excluded based on
the published information. Like the review by Synnot 2014, some
outcomes reported in the included study were not assessed in this
review because they were not prespecified outcomes, such as de-
cisional satisfaction. Similarly, we collected only one outcome for
each prespecified outcome category, and made this judgement on
a hierarchy of measures (such as from validated objective measure
to study specific non-validated measures).
The included study reported three different measures of knowl-
edge (two developed for use in the study with no validation data
reported and one validated subjective measure (Joffe 2001)). As
the authors did not specify whether they ranked the knowledge
outcomes, we chose to report the more robust data collected using
a validated measure. This was also the case for recruitment to the
parent trial, which was also reported three ways (attitude towards
parent trial (IBIS-II), intention to participate, and percentage ac-
tually enrolled), of which we chose percentage actually enrolled.
Further consideration and revision of the outcomes reported in
this review may be required in future updates.
The biggest potential threat of bias to this review arose from the
possibility that we did not identify all relevant published and un-
published studies. As part of a larger program of work, a formal
survey of the Directors of UK registered Clinical Trials Units, and
informal assessment of decision aid researchers through social me-
dia was conducted to determine if any work was being carried out
in this area. No reports were identified. The lead researchers of
those studies included in the Characteristics of ongoing studies
were also asked whether they were aware of any other research in
this area, of which none was reported.
Agreements and disagreements with other
studies or reviews
Due to the inclusion of only one study (reporting two decision aid
trials) with relatively small sample sizes, and the inconclusive find-
ings of the review, we were unable to make clear comparisons with
other studies or reviews. If future updates of this review include
more studies, there may be areas for direct comparison. Specifi-
cally, it would be interesting to draw comparisons between this re-
view and others investigating the effectiveness of different types of
interventions for informed consent to clinical trials (Flory 2004;
Hon 2012; Nishimura 2013; Synnot 2014). Due to the lack of
research comparing informed consent for research and informed
consent for treatment, it would also be interesting to compare the
findings from this reviewwith theCochrane review of decision aids
for treatment and screening decisions, which have been shown to
have an effect across several outcome domains such as knowledge,
decisional conflict and values clarification (Stacey 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was insufficient evidence to determine if decision aids to
support the informed consent process for clinical trials participants
are more effective than existing approaches. The pooled findings
from the included decision aid trials highlight considerable un-
certainty surrounding most of the outcomes reported (knowledge,
decisional conflict, anxiety, trial participation and trial attrition).
There was very low quality evidence indicating that decision aids
may lower levels of decisional regret. In addition, several primary
outcomes (important for the decision process) identified as being
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of importance were not reported. These included accurate risk ex-
pectations; reaching choices that are consistent with personal val-
ues; or whether potential participants recognised that a decision
needed to be made, were able to identify features of options that
matter most to individuals, or were involved in the decision. Al-
though the findings from Stacey 2014 suggest that decision aids
are more effective than standard consent processes for treatment
and screening, the applicability of these findings in the context
of consent for clinical trials remains equivocal and requires more
research.
Implications for research
The findings from this review highlight a gap in the evidence base.
More high quality RCTs of decision aids to support the informed
consent process for clinical trials are needed. Evidence is needed
from sufficiently powered (in terms of recruitment and analysis)
trials across various trial populations (both in terms of clinical
conditions, but also with regard to low literacy etc.), considering
different interventions (e.g. comparison of drug versus surgery;
behavioural intervention versus standard care), with measurement
of relevant outcomes at appropriate time points.
The outcomes that should be assessed in future trials in this context
requires further work (Gillies 2014e) but as a start could consider
knowledge; decision conflict; satisfaction with the decision mak-
ing process; values congruence; anxiety; and trial specific measures
(recruitment and retention). Where possible, validated objective
measures should be used to increase the study’s validity but also to
enable meaningful comparison across studies when combined in
systematic reviews. In addition, due to the problems with access-
ing and locating interventions from published studies, researchers
should make efforts for interventions (or intervention manuals)
to be accessible post-publication, for example, various formats of
interventions stored securely or accessible through web links in
published article. This reporting and availability of interventions
should also be extended to include a description of comparators,
especially when describing standard or usual information.
Through both design and reporting, trialists should strive to min-
imise bias through and refer to the CONSORT statement and
TIDieR checklist (a template for the reporting of interventions to
enable better replication) for guidance on the issue (www.consort-
statement.org; Hoffman 2014). Moreover, trialists should recog-
nise the potential difficulties associated with conducting trials
within trials (irrespective of focus) and ensure these are considered
when designing nested RCTs (Graffy 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Juraskova 2014 (DCIS)
Methods Multicentre international RCT of decision aid nested within a parent breast cancer
treatment RCT, a component of the IBIS II trial (Cuzick 2008).
Two armed trial (intervention plus standard information vs. standard information alone)
Participants This nested RCT of decision aids was set within the treatment trial component of the
IBIS II breast cancer trial. The parent treatment trial included postmenopausal women
who had received surgery for DCIS and were subsequently randomised to anastrozole or
tamoxifen for five years. A sample of participants being approached to participate in the
parent trial were first randomised to a nested RCT of a decision aid for trial participation
plus standard information or standard information alone before being randomised to
treatment allocation
All participants were postmenopausal women recruited across sites in Australia, New
Zealand and the UK
67 participants were randomised from the DCIS parent RCT;
34 were included in T1 analysis (post-decision) and 24 were included in the T2 analysis
(3 month follow up):
• Intervention: 19 at T1, 14 at T2
• Control: 15 at T1, 10 at T2.
Of the participants included in the T1 analysis the mean age was 58.5 years (SD 3.9) in
the intervention group and 58.7 years (SD 5.0) in the control group; 22 were married
(15 in intervention and 7 in control); 31 had at least high school education or higher
(18 in intervention and 13 in control); 20 were in managerial or professional work roles
(10 in intervention and 10 in control); and 31 only spoke English (17 in intervention
and 14 in control)
Interventions The decision aid booklet was designed to include evidence-based representation of breast
cancer risk, the IBIS-II trial rationale, explanation of management options available
on and off the trial, a comparison of the risks and benefits of each option, and values
clarification worksheets. Authors state that decision aids were designed to meet IPDAS
guidelines for content development. Intervention group received the standard parent
RCT information sheet (no details given in publication as to content) and the decision
aid booklet
Intervention development: paper states similar development process as has been pub-
lished in full elsewhere (Juraskova 2008) but there were no explicit details for this inter-
vention.
Exposure: once
Training for delivery of intervention: no details
Evaluation of the delivery of intervention: no details
Intervention type: booklet
Time of delivery: Exact timing of delivery not clear, during recruitment consultation for
parent trial
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Juraskova 2014 (DCIS) (Continued)
Outcomes At T1 (post-decision)
Primary outcome: difficulty with decision making (decisional conflict measure, which
contains 16 items each rated on a 1 to 5 Likert scale)
Secondary outcomes:
• Knowledge about clinical trials generally and the IBIS-II trial specifically (study
specific measures (7-item general knowledge and 12 (prevention) and 16 (DCIS)
objective understanding; and QuIC Part B, a 14 item measure);
• Attitudes toward participating in the trial (a 9-item scale adapted from attitude
scale);
• Anxiety (using 6-item short form State-Trait Anxiety Inventory (STAI) scale).
At T2 (3 month follow-up)
• Decisional satisfaction (using the 6-item Satisfaction with Decision (SWD) scale);
• Decisional regret (a 5-item Decisional Regret Scale);
• Intention to participate;
• Actual enrolment;
• Drop-out at end of trial.
Notes This study was supported by Susan G. Komen for the Cure (grant number
BCTR0503961) and discretionary funding from the Breast Cancer Institute of Australia,
which is the fundraising and education department of the Australia and New Zealand
Breast Cancer Trials Group (ANZBCTG; no grant number)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence was generated us-
ing a web-based random number genera-
tor (www.randomizer.org). Randomisation
was performed in blocks of 10 according to
centre
Allocation concealment (selection bias) Low risk Pre-randomised, sequentially numbered,
sealed envelopes were provided
Incomplete outcome data (attrition bias)
All outcomes
High risk The authors report that there were no dif-
ferences (in terms of rates and reasons) for
drop out in both arms. However, 66 par-
ticipants (23% of those randomised) were
not included in the analysis due to previ-
ous participation in a clinical trial which
may result in ceiling effects for several of
the measures. This was a post-randomisa-
tion decision
Selective reporting (reporting bias) Unclear risk Protocol not available. All outcomes listed
in the methods are reported in the results
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Juraskova 2014 (DCIS) (Continued)
Other bias Unclear risk Recruitment problems with DCIS cohort
reduced power
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded to interven-
tion received, but this would not be pos-
sible. Recruiters were blinded to interven-
tion group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Authors state that outcome assessors were
not blinded, likely because most outcomes
were patient reported
Juraskova 2014 (Prevention)
Methods Multicentre international RCT of decision aid nested within a parent breast cancer
prevention RCT, a component of IBIS II (Cuzick 2008).
Two armed trial (intervention plus standard information vs. standard information alone)
Participants This nested RCT of decision aids was set within the prevention trial of the IBIS II
breast cancer trial. The parent prevention trial aimed to randomise postmenopausal
women, who were at high risk of breast cancer (based on family history, previous benign
disease or mammographically dense breasts), to anastrozole or placebo for five years. A
sample of participants being approached to participate in the parent prevention trial
were first randomised to a nested RCT of a decision aid for trial participation plus
standard information or standard information alone before randomisation to prevention
allocation
All participants were postmenopausal women recruited across sites in Australia, New
Zealand and the UK
223 participants were randomised from the prevention parent trial
112 were included in T1 analysis (post-decision) and 95 were included in the T2 analysis
(3 month follow up):
• Intervention: 54 at T1, 44 at T2
• Control: 58 at T1, 51 at T2.
Of the participants included in the T1 analysis the mean age was 59.2 (SD 5.9) years in
the intervention group and 59.2 (SD 5.3) years in the control group; 90 were married
(43 in intervention and 47 in control); 111 had at least high school education or higher
(52 in intervention and 59 in control); 55 were in managerial or professional work roles
(28 in intervention and 27 in control); and 110 only spoke English (53 in intervention
and 57 in control)
Interventions The decision aid booklet was designed to include evidence-based representation of breast
cancer risk, the IBIS-II trial rationale, explanation of management options available
on and off the trial, a comparison of the risks and benefits of each option, and values
clarification worksheets. Authors state that decision aids were designed to meet IPDAS
guidelines for content development. Intervention group received the standard parent
RCT information sheet (no details given in publication as to content) and the decision
aid booklet
Intervention development: published in full elsewhere (Juraskova 2008)
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Juraskova 2014 (Prevention) (Continued)
Exposure: once
Training for delivery of intervention: no details
Evaluation of the delivery of intervention: no details
Intervention type: booklet
Time of delivery: Exact timing of delivery not clear, during recruitment consultation for
parent trial
Outcomes At T1 (post-decision)
Primary outcome: difficulty with decision making (decisional conflict measure, which
contains 16 items each rated on a 1 to 5 Likert scale)
Secondary outcomes:
• Knowledge about clinical trials generally and the IBIS-II trial specifically (study
specific measures (7-item general knowledge and 12 (prevention) and 16 (DCIS)
objective understanding; and QuIC Part B, a 14-item measure);
• Attitudes toward participating in the trial (a 9-item scale adapted from attitude
scale);
• Anxiety (using 6-item short form State-Trait Anxiety Inventory (STAI) scale).
At T2 (3 month follow-up)
• Decisional satisfaction (using the 6-item Satisfaction with Decision (SWD) scale);
• Decisional regret (a 5-item Decisional Regret Scale); intention to participate;
• Actual enrolment;
• Drop-out at end of trial
Notes This study was supported by Susan G. Komen for the Cure (grant number
BCTR0503961) and discretionary funding from the Breast Cancer Institute of Australia,
which is the fundraising and education department of the Australia and New Zealand
Breast Cancer Trials Group (ANZBCTG; no grant number)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence generated us-
ing a web-based random number genera-
tor (www.randomizer.org). Randomisation
was performed in blocks of 10 according to
centre
Allocation concealment (selection bias) Low risk Pre-randomised, sequentially numbered,
sealed envelopes were provided
Incomplete outcome data (attrition bias)
All outcomes
High risk The authors report that there were no dif-
ferences (in terms of rates and reasons) for
drop out in both arms. However, 66 partic-
ipants (30% of those randomised) were not
included in the analysis of the prevention
trial due to previous participation in a re-
lated clinical trial (IBIS I). The authors’ jus-
tificationwas that inclusionof these partici-
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Juraskova 2014 (Prevention) (Continued)
pantsmay result in ceiling effects for several
of the measures. This was a post-randomi-
sation decision. Although the sample sizes
were small, the proportion of excluded par-
ticipants did differ (qualitatively) between
arms (T1: 40% in DA group vs. 35% in
control; andT3: 40% inDA group vs. 30%
in control group)
Selective reporting (reporting bias) Unclear risk Protocol not available. All outcomes listed
in the methods are reported in the results
Other bias Low risk None reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded to interven-
tion received but this would not be pos-
sible. Recruiters were blinded to interven-
tion group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Authors state that outcome assessors were
not blinded likely because most outcomes
were patient reported
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abhyankar 2011 Intervention is not a decision aid. Study presents a RCT of a values clarification exercise
(implicit versus explicit) to support decisions about (hypothetical) trial participation.
Whilst values clarification exercises are a component of a decision aid these interventions
do not meet the full IPDASi criteria
Agre 2003 A review paper that presents data from six studies. The interventions included are ei-
ther not decision aids (e.g. enhanced information sheets, video information, computer
based) or not decision aids for trial participation (present a decision aid about testing for
haemophilia)
Agre 2003a Intervention ineligible. Authors were contacted for intervention and responded. Authors
unable to locate intervention. However, from details in published article and from a
Cochrane review on a similar topic (Synnot 2014) the intervention is not likely to be a
decision aid (standard consent information adjusted for reading age and then transferred
to booklet, video or computer delivery)
Benson 1988 Intervention ineligible. Authors were contacted and responded. Interventions could not
be located. Fromdetails in published article and fromaCochrane reviewon a similar topic
(Synnot 2014) intervention not likely to be a decision aid (e.g. video-based ’instructional’
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(Continued)
video and ’improvements’ to investigators discussions with potential participants)
Content: The videotapes employed were described as ’instructional’ (standard) and ’im-
proved’ for the two different intervention components. The standard video format in-
volved the principal investigator or other designated project staff from the psychiatric
trials describing the study as he/she chose to do so. This typically reflected the usual pre-
sentation made to subjects at the time of consent. The improved video format included
feedback from the research team about areas of the disclosure that could be improved or
required greater emphasis. Following this feedback, the second ’improved’ video format
was produced. (taken from Synnot 2014)
Dear 2012 Intervention not a decision aid. Described as “consumer-friendly cancer clinical trials
web site” that enables people to search for trials, contains general information about
trials and provides a list of questions that people might want to ask if considering trial
participation
Dunn 2002 Intervention ineligible. Unable to assess intervention content for inclusion. Authors
were contacted for intervention and responded but intervention could not be located.
From details in published article and those provided by author, the intervention is not
likely to be a decision aid. Intervention described as a computer based intervention that
was composed of PowerPoint slides that provided a more structured review of the same
material that was in the consent form
Eccles 2013 Intervention not a decision aid for trial participation. Decision aid for treatment or
screening
Foradori 2012 Intervention not a decision aid for trial participation. Decision aid for treatment or
screening
Hoffner 2012 Intervention not a decision aid. Video-based intervention developed by a US cancer
centre. The aim of the videowas to improve patients knowledge about trials by explaining
clinical trials in a clear, simple, and balanced way
Hutchison 2007 Intervention not a decision aid. Intervention delivered as an audio-visual video based
tool and covered both generic and cancer site specific information, with a particular focus
on randomisation
Jacobsen 2012 Intervention not a decision aid. A psycho-educational multimedia intervention that
contained generic information about clinical trials and covered “misperceptions and
concerns about clinical trials”
Lurie 2011 Intervention not a decision aid for trial participation. Decision aid for treatment or
screening
Meropol 2013 Intervention not a decision aid. Tailored videos selected by participant presented on a
web-based platform. Some components could be considered aspects of a decision aid,
but as a whole, the intervention does not meet the IPDASi criteria
National Prescribing Centre (NHS) 2007 Non-eligible study design. Discussion piece
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(Continued)
Norris 1990 Intervention ineligible. No contact details for author. From details in published article
and from a Cochrane review on a similar topic (Synnot 2014) the intervention is not
likely to be a decision aid.
Content: Information on the study protocol and adherence to the study protocol, in-
cluding the following: compliance with dosing schedules; maintenance of diary cards;
adherence to specific antacid limitations; presence at scheduled follow-up visits; proce-
dures to be used; possible adverse reactions; study consent forms; and who to call for
information (taken from Synnot 2014)
Pinto 2008 Intervention not a decision aid for trial participation. Study reports RCT pilot for treat-
ment, which also includes patient preference arm, but no consent interventions
Saver 2007 Intervention not a decision aid for trial participation. Decision aid for treatment or
screening
Sundaresan 2011 Non-eligible study design. Mixed-methods pilot of decision aid for trial participation.
See Characteristics of ongoing studies
Tait 2010 Intervention not a decision aid. RCTof differentmethods for presenting risk information
to parents facing a hypothetical decision about their child’s participation in an RCT.
Components of intervention could be considered aspects of a decision aid, but as a whole,
the intervention does not meet the IPDASi criteria
Ubel 1997 Intervention ineligible. Unable to assess intervention content for inclusion. Authors
were contacted and responded stating intervention not a decision aid. From details in
published article review authors also concluded intervention not likely to be a decision
aid
Weston 1997 Intervention ineligible. Authors were contacted and responded. Interventions could not
be located. From details in published article and from a Cochrane review on a similar
topic (Synnot 2014) intervention not likely to be a decision aid.
Content: Included description of the medical condition, pre labour rupture of mem-
branes at term (Term PROM); and description of the study, including: the manoeuvre
- showing actual patients receiving each treatment, the risks and benefits of all study
groups, the benefits of participating in clinical research and important aspects of the trial
protocol, described by the principal investigator. An actual trial participant also described
why she had participated in the study, the contribution she felt it made to medical sci-
ence and to future women. An invitation to participate in the study and instructions on
where to obtain further information on study participation were also included (taken
from Synnot 2014)
Wragg 2000 Intervention ineligible. Authors were contacted and responded, interventions could not
be located. From details in published article and from a Cochrane review on a similar
topic (Synnot 2014) intervention not likely to be a decision aid.
The comparison was different framingmessages used in amulti-component intervention
(taken from Synnot 2014)
Zwitter 1997 Non-eligible study design. Discussion piece
34Decision aids for people considering taking part in clinical trials (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of ongoing studies [ordered by study ID]
Byrne
Trial name or title Participation in cancer clinical trials: Improving minority cancer patient informed decision making through
use of a patient centred decision aid
Methods Pilot RCT
Participants Cancer patients who:
• have a type and stage of cancer where there is the potential for a trial to be available to the
and
• are Hispanic, Black, or other minority patients.
Interventions Web based decision aid
Outcomes • Objective knowledge
• Preparedness for making decisions about cancer clinical trials
• Attitudes about cancer clinical trials
Starting date 2014
Contact information Margaret Byrne
MByrne2@med.miami.edu
Notes
Politi
Trial name or title A Mixed Methods Study to Reduce Disparities in Cancer Clinical Trials by Adapting a Health Literacy
Intervention for Informed Consent and Comparing it to Usual Care in a Randomized Experiment
Methods RCT
Participants Inclusion criteria:
• Diagnosed with cancer in the past 6 months
• English speaking
• At least 18 years old
Exclusion criteria:
• Past participation in a clinical trial for treatment
Interventions A targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care
Outcomes Primary outcome measures:
• Knowledge about cancer clinical trials
Secondary outcome measures:
• Self-efficacy for communicating about cancer clinical trials
• Attitudes about cancer clinical trials
• Satisfaction with the information presented
• Confidence in choice
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Politi (Continued)
Starting date 2014
Contact information Mary C Politi PhD
mpoliti@wustl.edu
Hannah E Perkins, MPA
perkinsh@wudosis.wustl.edu
Notes
Sundaresan
Trial name or title Evaluating the Utility of a Patient Decision Aid for Prospective Participants in the TROG RAVES Prostate
Cancer Trial (TROG 08.03)
Methods RCT
Participants • men with prostate cancer with positive margins
• and/or stage pT3 disease following radical prostatectomy
• aged > 18 years
Interventions Decision aid
Outcomes • Decisional conflict
• Recruitment
• Drop-out rates
• Knowledge about clinical trials
• Attitudes towards participating
• Anxiety
• Decisional regret
• Decisional satisfaction
Starting date 2014
Contact information Dr Puma Sundaresan
puma.sundaresan@sswahs.nsw.gov.au
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Comparison 1: Decision aid for informed consent versus standard informed consent
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Knowledge 2 146 Mean Difference (IV, Random, 95% CI) 1.68 [-1.91, 5.26]
2 Decisional conflict 2 146 Mean Difference (IV, Random, 95% CI) 3.47 [-1.51, 8.45]
3 Decisional regret 2 119 Mean Difference (IV, Random, 95% CI) -5.53 [-10.29, -0.76]
4 Participation 2 146 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.76, 1.48]
5 Attrition 2 71 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.51, 4.68]
6 Anxiety 2 146 Mean Difference (IV, Random, 95% CI) -2.38 [-10.65, 5.90]
Analysis 1.1. Comparison 1 Comparison 1: Decision aid for informed consent versus standard informed
consent, Outcome 1 Knowledge.
Review: Decision aids for people considering taking part in clinical trials
Comparison: 1 Comparison 1: Decision aid for informed consent versus standard informed consent
Outcome: 1 Knowledge
Study or subgroup Decision aid Standard
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Juraskova 2014 (DCIS) 19 88.9 (12.5) 15 83.2 (25.6) 6.4 % 5.70 [ -8.42, 19.82 ]
Juraskova 2014 (Prevention) 54 93.4 (10.1) 58 92 (9.9) 93.6 % 1.40 [ -2.31, 5.11 ]
Total (95% CI) 73 73 100.0 % 1.68 [ -1.91, 5.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours standard Favours DA + standard
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Analysis 1.2. Comparison 1 Comparison 1: Decision aid for informed consent versus standard informed
consent, Outcome 2 Decisional conflict.
Review: Decision aids for people considering taking part in clinical trials
Comparison: 1 Comparison 1: Decision aid for informed consent versus standard informed consent
Outcome: 2 Decisional conflict
Study or subgroup Decision aid Standard
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Juraskova 2014 (DCIS) 19 20.7 (25.4) 15 11.9 (10.9) 15.4 % 8.80 [ -3.88, 21.48 ]
Juraskova 2014 (Prevention) 54 15.7 (14.7) 58 13.2 (14.5) 84.6 % 2.50 [ -2.91, 7.91 ]
Total (95% CI) 73 73 100.0 % 3.47 [ -1.51, 8.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours DA + standard Favours standard
Analysis 1.3. Comparison 1 Comparison 1: Decision aid for informed consent versus standard informed
consent, Outcome 3 Decisional regret.
Review: Decision aids for people considering taking part in clinical trials
Comparison: 1 Comparison 1: Decision aid for informed consent versus standard informed consent
Outcome: 3 Decisional regret
Study or subgroup Decision aid Standard
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Juraskova 2014 (DCIS) 14 16.9 (17.4) 10 20.5 (12.1) 16.3 % -3.60 [ -15.40, 8.20 ]
Juraskova 2014 (Prevention) 44 10.1 (11.8) 51 16 (14.1) 83.7 % -5.90 [ -11.11, -0.69 ]
Total (95% CI) 58 61 100.0 % -5.53 [ -10.29, -0.76 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours DA + standard Favours standard
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Analysis 1.4. Comparison 1 Comparison 1: Decision aid for informed consent versus standard informed
consent, Outcome 4 Participation.
Review: Decision aids for people considering taking part in clinical trials
Comparison: 1 Comparison 1: Decision aid for informed consent versus standard informed consent
Outcome: 4 Participation
Study or subgroup Decision aid Standard Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Juraskova 2014 (DCIS) 11/19 9/15 34.0 % 0.96 [ 0.55, 1.70 ]
Juraskova 2014 (Prevention) 26/54 25/58 66.0 % 1.12 [ 0.75, 1.67 ]
Total (95% CI) 73 73 100.0 % 1.06 [ 0.76, 1.48 ]
Total events: 37 (Decision aid), 34 (Standard)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours standard Favours DA + standard
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Analysis 1.5. Comparison 1 Comparison 1: Decision aid for informed consent versus standard informed
consent, Outcome 5 Attrition.
Review: Decision aids for people considering taking part in clinical trials
Comparison: 1 Comparison 1: Decision aid for informed consent versus standard informed consent
Outcome: 5 Attrition
Study or subgroup Decision aid Standard Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Juraskova 2014 (DCIS) 4/11 2/9 57.9 % 1.64 [ 0.38, 6.98 ]
Juraskova 2014 (Prevention) 3/26 2/25 42.1 % 1.44 [ 0.26, 7.92 ]
Total (95% CI) 37 34 100.0 % 1.55 [ 0.51, 4.68 ]
Total events: 7 (Decision aid), 4 (Standard)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours standard Favours DA + standard
Analysis 1.6. Comparison 1 Comparison 1: Decision aid for informed consent versus standard informed
consent, Outcome 6 Anxiety.
Review: Decision aids for people considering taking part in clinical trials
Comparison: 1 Comparison 1: Decision aid for informed consent versus standard informed consent
Outcome: 6 Anxiety
Study or subgroup Decision aid Standard
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Juraskova 2014 (DCIS) 19 29.6 (8.7) 15 36.7 (10.9) 44.4 % -7.10 [ -13.86, -0.34 ]
Juraskova 2014 (Prevention) 54 31 (10.7) 58 29.6 (10) 55.6 % 1.40 [ -2.44, 5.24 ]
Total (95% CI) 73 73 100.0 % -2.38 [ -10.65, 5.90 ]
Heterogeneity: Tau2 = 28.25; Chi2 = 4.59, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours DA+ standard Favours standard
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials
#1 MeSH descriptor: [Clinical Trials as Topic] explode all trees
#2 MeSH descriptor: [Longitudinal Studies] explode all trees
#3 MeSH descriptor: [Evaluation Studies as Topic] this term only
#4 MeSH descriptor: [Pilot Projects] explode all trees
#5 MeSH descriptor: [Research Subjects] this term only
#6 MeSH descriptor: [Informed Consent] this term only
#7 MeSH descriptor: [Patient Participation] this term only
#8 MeSH descriptor: [Refusal to Participate] this term only
#9 (clinical or intervention or evaluation or comparative) next stud*:ti,ab,kw
#10 (longitudinal or follow-up or followup or prospective) next stud*:ti,ab,kw
#11 (multi-center or multicenter or multi-centre or multicentre) next stud*:ti,ab,kw
#12 (research or study) next (subject* or participant*):ti,ab,kw
#13 ((particpa* or (tak* next part) or enrol* or recruit*) near/6 (research or stud* or experiment*)):ti,ab,kw
#14 (informed near/2 (consent or decision* or choice)) .ti,ab,kw
#15 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 in Trials
#16 MeSH descriptor: [Decision Support Techniques] this term only
#17 MeSH descriptor: [Decision Support Systems, Clinical] this term only
#18 MeSH descriptor: [Decision Trees] this term only
#19 MeSH descriptor: [Decision Making, Computer-Assisted] this term only
#20 MeSH descriptor: [Decision Making] this term only
#21 MeSH descriptor: [Choice Behavior] this term only
#22 computer* near/1 “decision making”:ti,ab,kw
#23 “risk communication” near/3 tool*:ti,ab,kw
#24 (decision next (board* or guide* or counseling)):ti,ab,kw
#25 (decision* or decid*) near/3 (support* or aid* or tool* or instrument*):ti,ab,kw
#26 (decision* or decid*) near/3 (technolog* or technique* or system* or program* or algorithm*):ti,ab,kw
#27 (decision* or decid*) near/3 (process* or method* or intervention* or material*):ti,ab,kw
#28 (interacti* near/3 tool*):ti,ab,kw
#29 (interactive next health next communication*):ti,ab,kw
#30 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 in Trials
#31 #15 and #30 in Trials (988)
MEDLINE
1. exp Clinical Trials as topic/ (296396)
2. exp Longitudinal Studies/ (883743)
3. Evaluation Studies as Topic/ (121291)
4. Pilot Projects/ (84444)
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5. Research Subjects/ (5215)
6. ((particpa$ or tak$ part or enrol$ or recruit$) adj7 (research or stud$ or experiment$ or trial?)).tw. (111720)
7. Informed Consent/ (31662)
8. (informed adj3 (consent or decision? or choice)).tw. (30027)
9. Patient Participation/ (18146)
10. Refusal to Participate/ (537)
11. OR/1-10 (1471406)
12. Decision Support Techniques/ (12281)
13. Decision Support Systems Clinical/ (5166)
14. Decision Trees/ (9021)
15. Decision Making/ (69125)
16. Choice Behavior/ (22303)
17. Decision-making Computer Assisted/ (2561)
18. ((decision$ or decid$) adj4 (support$ or aid$ or tool$ or instrument$ or technolog$ or technique$ or system$ or program$ or
algorithm$ or process$ or method$ or intervention$ or material$)).tw. (45833)
19. (decision adj (board$ or guide$ or counseling)).tw.(125)
20. (risk communication adj4 tool$).tw. (51)
21. (computer$ adj2 decision making).tw. (151)
22. interactive health communication$.tw. (60)
23. (interacti$ adj4 tool$).tw. (2387)
24. OR/12-23 (146628)
25. 11 AND 24 ( 22784)
26. Randomized Controlled Trial.pt. (390288)
27. Controlled Clinical Trial.pt. (89931)
28. randomi?ed.ab (372420)
29. placebo.ab. (164048)
30. randomly.ab. (216716)
31. trial.ti. (132126)
32. exp animals/ not humans/ (8160129)
33. OR 26-31 (838352)
34. 33 NOT 32 (767535)
35. 25 AND 34 (3268)
EMBASE
1. exp “Clinical Trial (topic)”/ (82009)
2. Longitudinal Study/ (65940)
3. Prospective Study/ (254724)
4. Intervention Study/ (17697)
5. Follow Up/ (760000)
6. Evaluation/ (190672)
7. clinical trial?.tw. (272070)
8. ((clinical or intervention or experimental or follow-up or followup or prospective or multi-center or multicenter or double blind
or pilot or random$ or control$ or crossover or cross-over) adj2 stud$).tw. (887369)
9. Research Subject/ (5272)
10. ((particpa$ or tak$ part or enrol$ or recruit$) adj7 (research or stud$ or experiment$ or trial?)).tw. (151174)
11. Informed Consent/ (61112)
12. (informed adj3 (consent or decision? or choice)).tw. (44998)
13. Patient Participation/ (16718)
14. Refusal to Participate/ (763)
15. OR/1-14 (2271179)
16. Decision Support System/ (12875)
17. Decision Tree/ (5735)
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18. Decision Making/ (136260)
19. ((decision$ or decid$) adj4 (support$ or aid$ or tool$ or instrument$ or technolog$ or technique$ or system$ or program$ or
algorithm$ or process$ or method$ or intervention$ or material$)).tw. (57075)
20. (decision adj (board$ or guide$ or counseling)).tw. (145)
21. (risk communication adj4 tool$).tw. (55)
22. (computer$ adj2 decision making).tw. (177)
23. interactive health communication$.tw. (55)
24. (interacti$ adj4 tool$).tw. (2548)
25. OR/16-24 (191815)
26. 15 AND 25 (31136)
27. exp Controlled Clinical Trial/ (494677)
28. Randomization/ (63887)
29. Crossover Procedure/ (38971)
30. Single Blind Procedure/ (18506)
31. Double Blind Procedure/ (118651)
32. randomi?ed.ab. (445792)
33. placebo.ab. (189562)
34. randomly.ab. (245999)
35. ((singl$ or doubl$) adj (blind$ or mask$)).tw.(157344)
36. random$.tw.(857492)
37. (assign* or allocat* or volunteer* or crossover or cross over or factorial* or latin square).tw. (553648)
38. nonhuman/ not human/ (3340797)
39. OR/27-37 (1500828)
40. 39 not 38 (1303193)
41. 26 and 40 (5713)
ASSIA
((SU.EXACT(“Clinical randomized controlled trials”) OR SU.EXACT(“Double blind randomized trials”) OR SU.EXACT(“Clinical
trials”) OR SU.EXACT(“Prospective controlled trials”) OR SU.EXACT(“Crossover trials”) OR SU.EXACT(“Single blind random-
ized controlled trials”) OR SU.EXACT(“Clustor randomized trials”) OR SU.EXACT(“Cluster randomized controlled trials”) OR
SU.EXACT(“Randomized controlled trials”) OR SU.EXACT(“Trials”) OR SU.EXACT(“Double blind randomized controlled trials”)
) OR ab((randomized or randomised or randomly OR (clinical or random*) N/3 trial)) OR ti((randomized or randomised or randomly
OR (clinical or random*) N/3 trial))) AND ((SU.EXACT(“Computerized decision support systems”) OR SU.EXACT(“Decision
support systems”) OR (SU.EXACT “decision making”) OR SU.EXACT(“Informed choice”) OR TI (decision* OR decid* OR choice)
OR AB (decision* OR decid* or choice))) (38)
PsycINFO
S1 ((DE “Experimentation”) OR (DE “Followup Studies” OR DE “Longitudinal Studies” OR DE “Prospective Studies”)) OR (DE
“Experimental Subjects”) (76469)
S2 TX ( (clinical or intervention or evaluation or comparative) W1 stud* ) OR TX ( (longitudinal or follow-up or followup or
prospective) w1 stud* ) OR TX ( (multi-center or multicenter or multi-centre or multicentre) w1 stud* ) OR TX (“double blind” or
pilot) w1 stud* )) (268381)
S3 TX ( (research W1 (subject* or participant*) OR TX ( study W1 (subject* or participant*) ) (21066)
S4 TX clinical trial* OR TX experiment* (581,412)
S5 DE “Experimental Methods” (8,670)
S6 DE “Clinical Trials” (7,124)
S7 DE “Informed Consent” (3208)
S8 TX (informed N3 (consent or decision* or choice)) (9261)
S9 DE “Client Participation” (1272)
S10 TX ( ((participan* or tak* part or enrol* or recruit*) N7 research) OR TX ((participan* or tak* part or enrol* or recruit*) N7
stud*) ) OR TX ((participan* or tak* part or enrol* or recruit*) N7 experiment*)) ) (95017)
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S11 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 (882,093)
S12 DE “Decision Support Systems” (2122)
S13 DE “Decision Making” OR DE “Choice Behavior” (57035)
S14 TX decision w1 tree? OR TX decision w1 board* OR TX decision w1 guide* OR TX decision w1 counseling (627)
S15 TX ( (decision* or decid*) N4 (support* or aid* or tool* or instrument*) ) OR TX ( (decision* or decid*) N4 (technolog* or
technique* or system* or program*) ) OR TX ( (decision* or decid*) N4 (algorithm* or process* or method* or intervention* or
material*) ) (34988)
S16 TX “risk communication” N4 tool* OR TX computer* N2 “decision making” OR TX interactive health communication* OR
TX interacti* N4 tool* (1227)
S17 S12 OR S13 OR S14 OR S15 OR S16 (78,752)
S18 TX random* OR TX trial* OR TX controlled stud* OR TX placeb*
S19 TX ( (singl* or doubl* or trebl* or tripl*) ) AND TX ( (blind* or mask*) ) (21,472)
S20 TX cross over OR TX crossover OR TX factorial* OR TX latin square (22,200)
S21 TX assign* OR TX allocat* OR TX volunteer* (114,294)
S22 (DE “Treatment Effectiveness Evaluation”) OR (DE “Mental Health Program Evaluation”) (17,190)
S23 DE “Experimental Design” OR DE “Between Groups Design” OR DE “Clinical Trials” OR DE “Cohort Analysis” OR DE
“Followup Studies” OR DE “Hypothesis Testing” OR DE “Longitudinal Studies” OR DE “Repeated Measures” (45,695)
S24 MR “2000” (25,297)
S25 S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 (339,493)
S32 S11 AND S17 AND S25 (1,123)
WH A T ’ S N E W
Last assessed as up-to-date: 5 March 2015.
Date Event Description
15 April 2015 Amended Since protocol publication the references have been updated throughout
14 June 2014 Amended Amendment to title
C O N T R I B U T I O N S O F A U T H O R S
• Katie Gillies: Did the preparatory research; wrote the title registration form, the protocol and the full review. Contributed to all
stages in the review process including refining search strategy; screening abstracts; data abstraction; data analysis; and write up. Wrote
the first draft of the manuscript and led the response to reviewers’ comments.
• Jamie Brehaut: Critically read the title registration form, protocol, and submitted review. Assessed titles and abstracts obtained
from electronic searches and contributed to the assessment of methodological quality of retrieved studies and the analysis of results.
• Seonaidh Cotton: Assessed titles and abstracts obtained from electronic searches and contributed to the assessment of
methodological quality of retrieved studies and the analysis of results. Critically read the submitted review.
• Mary Politi: Critically read the title registration form and the submitted protocol. Assessed eligibility of studies for inclusion.
Critically read the submitted review.
• Zoe Skea: Critically read the title registration form, protocol, and submitted review. Assessed the titles and abstracts obtained
from electronic searches and contributed to the assessment of methodological quality of retrieved studies and the analysis of results.
Critically read the submitted review.
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D E C L A R A T I O N S O F I N T E R E S T
• Jamie Brehaut: None known.
• Seonaidh Cotton: None known.
• Katie Gillies: None known.
• Mary Politi: From 2011 to 2013, I was on the US Prescription Medication Adherence Advisory Board for Merck. My role on
this advisory board is not related to this Cochrane review which is about patient decision aids for clinical trials, and is unrelated to
medication adherence. I have a current investigator-initiated proposal funded by Merck to examine a decision aid about cancer
clinical trials. This decision aid is not included in the review and the trial is ongoing. (See Ongoing studies).
• Zoe Skea: None known
S O U R C E S O F S U P P O R T
Internal sources
• University of Aberdeen, UK.
Infrastructure support to review authors and information scientist (C Fraser)
• Washington University School of Medicine, USA.
Infrastructure support to review author
• Ottawa Hospital Research Institute, Canada.
Infrastructure support to review author
• University of Ottawa, Canada.
Infrastructure support to review author
External sources
• Chief Scientist Office of the Scottish Government Health Directorate, UK.
Provided personal fellowship award to Dr Gillies.
• Medical Research Council, UK.
Provided personal fellowship award to Dr Gillies
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title of the review was changed since the protocol was published. In the protocol the interventions being evaluated were described as
“decision support interventions”; however, this has been clarified in the review to “decision aids” to accurately reflect the interventions
that were searched for in included studies and the prespecified nature of the interventions in the protocol.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Clinical Trials as Topic; ∗Decision Making; ∗Decision Support Techniques; ∗Informed Consent; ∗Patient Participation; Randomized
Controlled Trials as Topic
MeSH check words
Humans
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